Salivary duct carcinoma (SDC) is a rare, aggressive salivary gland malignancy with limited evidence guiding standard treatment. SDC is known to overexpress the androgen receptor, with only a handful of cases reporting responses to androgen blockade. This report presents a case of SDC responding to multiple lines of androgen blockade, including a rapid response to abiraterone, a CYP17 inhibitor effective in prostate cancer. This case represents the first published report of SDC responding to abiraterone and illustrates that androgen receptor expressing SDC may be treated with multiple lines of androgen blockade, including newer agents such as abiraterone. This case suggests that SDC may continue to be androgen-dependent after progression on androgen deprivation, which is analogous to prostate cancer. (J Natl Compr Canc Netw 2015;13:288-290) cently shown significant efficacy in castration-resistant prostate cancer, 5, 6 but reports of its use in SDC have not been published.
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This report describes what seems to be the first published clinical and radiologic response to abiraterone in a patient with metastatic SDC refractory to bicalutamide and goserelin.
Case Report
A previously healthy, 45-year-old man with no smoking history presented in October 2011 with a right-sided neck mass. Imaging studies, including a CT and fluorodeoxyglucose (FDG)-PET/CT, showed enlarged level II and V right neck nodes with a lesion in the right parotid gland. An open biopsy of a lymph node confirmed adenocarcinoma.
Subsequently, the patient underwent a right parotidectomy and modified neck dissection. Pathologic assessment showed an SDC within the parotid gland with extracapsular extension, positive margins, and 57 of 57 lymph nodes involved. Diagnosis was confirmed with immunohistochemical stains being positive for GCD-FP-15, CK7, and AR, and negative staining for c-kit, CK20, and HER2.
The patient received 60 Gy of postoperative radiotherapy in 30 fractions and then adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin (CAP). During the third cycle of chemotherapy, a palpable contralateral lymph node appeared and fine-needle aspiration cytology confirmed recurrence. An FDG-PET/CT demonstrated that this left cervical lymph node and an additional sclerotic left iliac bone metastasis. Anti-androgen therapy was initiated with goserelin, and a short-term partial metabolic response of 4 months' duration was shown by Salivary duct carcinoma (SDC) is a rare cancer representing less than 10% of all salivary gland malignancies. 1, 2 It is an aggressive tumour, with many patients succumbing to disseminated disease. 3 Given its rarity, no standard treatment exists for metastatic SDC.
Androgen receptors (ARs) are overexpressed in most SDCs, and reports have shown some activity with anti-androgen therapy using bicalutamide with or without goserelin. 4 Abiraterone, by inhibiting adrenal and testicular androgen synthesis through CYP17, has re-FDG-PET/CT. At progression, combined androgen deprivation with the addition of bicalutamide provided a good metabolic response for a further 10 months. At this time, PET/CT scan revealed progressive disease in the neck and skeleton, and a repeat biopsy confirmed persistent strong AR expression (Figure 1) .
Extrapolating from recent prostate cancer trials, abiraterone at a dosage of 1000 mg/d with prednisone, 5 mg twice daily (with ongoing goserelin) was commenced, and within 3 weeks a complete clinical response was seen within the cervical neck lymph node. A PET/CT scan at 3 months confirmed resolution of FDG uptake in the neck ( Figure 2 ) and a significant favorable metabolic response in the skeletal metastases. At 6 months, PET/CT confirmed ongoing response. After 10 months on abiraterone and goserelin, increasing pain in the sacrum was described and a repeat PET/CT confirmed progressive osteoblastic bone disease with ongoing control of the neck disease. Until this point, no radiotherapy was delivered to bone metastases. Abiraterone was well tolerated with no unexpected side effects.
Discussion
Salivary gland malignancies are diagnosed in 1.3 per 100,000 persons, constituting 12.0% of oral cavity/ pharyngeal malignancies and less than 0.5% of all cancers in the United States. 7 Salivary gland carcinomas are divided into 24 different entities by the WHO, including mucoepidermoid, adenoid cystic carcinoma, adenocarcinoma, and SDC, with the last accounting for up to 9% of salivary gland malignancies. Nuclear reactivity for ARs has been reported to occur in more than 40% to 93% of SDCs. 8, 9 In fact, the WHO maintains that all SDCs show strong nuclear reactivity for ARs. 1 Given the rarity of SDC and the resultant lack of high-quality evidence, no standard treatment guidelines exist. Evidence suggests that SDC is associated with potentially targetable molecular abnormalities, including AR expression, 10 HER2 overexpression, 11 and, rarely, EGFR mutations, 12 PIK3CA-activating, or BRAF-activating mutations. 13 However, responses to specific molecular targeting is limited to single or few case reports.
It has been suggested that SDC may be similar to prostate cancer with respect to androgen dependence and to breast cancer with respect to histology and HER2 overexpression 9, 12, 14 Given the rarity of SDC, treatment options for SDC may be inferred from both these cancers. Responses to trastuzumab 11 and androgen deprivation therapy in SDC have been described in case reports [14] [15] [16] and a case series. 4 The case series described 2 partial responses and 3 patients with stable disease among 10 patients (clinical benefit of 50%) with AR-positive SDC treated with androgen deprivation. Nine of 10 patients received single-agent bicalutamide as first-line therapy, with 3 patients receiving second-line androgen deprivation therapy with the addition of goserelin. However, no radiologic responses were reported in patients receiving second-line therapy. Because of the limited number of reports of androgen deprivation in ARexpressing SDC, the most effective strategy to inhibit the androgen pathway in SDC is unknown.
It has been established that castration-resistant prostate cancer remains dependent on androgen stimulation for survival and progression. 17 Furthermore, enzymes involved in the synthesis of androgens, including CYP17, are overexpressed in prostate cancer. 18 Abiraterone, an irreversible inhibitor of CYP17, thereby inhibits the synthesis of andro- gens in the testes and adrenal glands, and in the tumor itself. It has recently shown significant activity in castration-resistant prostate cancer, with an improvement in overall survival in patients previously treated with chemotherapy, 5 and an increase in progression-free survival in chemotherapy-naïve patients. 6 The 10-month progression-free survival seen in the present patient while on abiraterone is remarkably similar to the median time to prostatespecific antigen progression of 10.5 months in castration-resistant prostate cancer. 5 The common side effects of abiraterone include mineralocorticoid effects caused by a compensatory increase in adrenocorticotropic hormone (ACTH), including hypertension, hypokalemia, and fluid retention, and, uncommonly, hepatotoxicity with an increase in bilirubin and/or hepatic transaminases. 5 Prednisone is prescribed together with abiraterone to prevent the compensatory increase in ACTH, and caution should be taken in patients with cardiovascular or hepatic disease. 
Conclusions
Patient response in the present case to multiple lines of androgen blockade, including abiraterone, suggests that androgen dependence also occurs in AR-expressing SDC, and that continued blockade of this pathway despite progression may be beneficial. Consequently, it may be reasonable to consider other inhibitors of the androgen axis that have been proven effective in prostate cancer, such as enzalutamide, in the treatment of this disease entity. In the absence of prospective clinical data, multiple lines of androgen deprivation therapy should be considered in patients with AR-expressing SDC, but the appropriate sequence of anti-androgen therapies is unknown. If feasible and when recruitment begins, preference should be given to enrollment on a prospective clinical trial comparing chemotherapy versus anti-androgen therapy (ClinicalTrials.gov identifier: NCT01969578) in androgen-expressing salivary gland carcinomas.
